Biceps TendonitisPhase 3NCT02741713
Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery
A Phase 3 study testing PECS "Pectoralis" 1 and 2 Blocks, Interscalene Block and Solution for Injection in Interscalene Block in people with Biceps Tendonitis, run by Wake Forest University Health Sciences at 1 site in United States.
Trial summary
The standard practice for arthroscopic shoulder surgery at our institution is a general anesthetic with a long-acting interscalene block for post-operative pain control, which can reduce the amount of opiates needed after surgery. Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Biceps Tendonitis
- What is being tested?
- PECS "Pectoralis" 1 and 2 Blocks, Interscalene Block and Solution for Injection in Interscalene Block
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2016to 29 Jun 2017
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adults, between 18 and 80 years of age
- Ability to take pills
- Agreement to a regional with general anesthesia technique
Who cannot join
- Allergy to amide local anesthetics
- Presence of a progressive neurological deficit
- pre-existing coagulopathy
- Current infection
- Significant pulmonary disease contraindicating phrenic nerve blockade
- Chronic use of an opioid analgesic (>3 months of a combined total of more than 40mg oxycodone equivalents a day)
- Inability to obtain ultrasound images of anatomy due to obesity.
- Pregnancy
Trial locations and contacts
1 site in 1 country.
United States1 site
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27157
About this study
The standard practice for arthroscopic shoulder surgery at our institution is a general anesthetic with a long-acting interscalene block for post-operative pain control, which can reduce the amount of opiates needed after surgery. The interscalene block is effective in providing analgesia to the majority of the shoulder joint and has been shown to reduce post-operative pain scores after arthroscopic shoulder surgeries. However, there is a subset of arthroscopic shoulder surgery patients who have pain in the axilla even in the setting of a functioning interscalene brachial plexus nerve block. One of our surgeons has reported a high incidence of axillary pain in patients who undergo a sub-pectoral biceps tenodesis as part of their arthroscopic procedure. A newly described nerve block approach to the nerves that supply sensation to the axillary region called the PECS "Pectoralis" 1 \& 2 block may provide additional analgesia to these patients.
The purpose of this prospective, randomized, observer and patient blinded, single-center, sham block trial is to determine if the addition of PECS blocks to an interscalene block will reduce the severity of axillary pain following arthroscopic shoulder surgery that involves a sub-pectoral biceps tenodesis. Secondarily, the study will assess the duration of PECS 1 \& 2 and whether the block reduces post-operative opioid usage. We hypothesize that the addition of the PECS 1 \& 2 block will reduce the severity of axillary pain at 6hrs and reduce postoperative narcotic usage for the first 24 hours.
Read the detailed description
Subjects that meet the inclusion criteria will be assigned a group by using a random numbers generator. All subjects will receive the standard practice at our institution of an interscalene brachial plexus block along with a general anesthetic. The intervention arm will get an additional local anesthetic block targeting nerves that we presume cover the axillary region (PECS "Pectoralis" 1 \& 2). These nerves in the upper chest are the lateral branches of the 2nd to 5th intercostal nerves, which includes the intercostobrachial nerve. The anesthesiologist placing the nerve blocks will be un-blinded to perform the procedures. Both the surgeon and the Acute Pain Service anesthesiologist will be blinded as to whether or not the intervention was provided to any given subject. The Acute Pain Service team will remain blinded and collect the data outcomes.
Initially, pilot data was collected in a total of ten patients with five patients randomized to each arm. Primary endpoint was NRS "Numerical Rating Scale" of 0-10 at 6hrs after block placement. Our pilot data indicate that the mean NRS is about 5 for the control group, with a standard deviation of 1.4. Using a two-sided two-sample t test (an alpha of 0.05 and power of 0.95), we conservatively estimate that 14 subjects per arm will be needed to detect a clinically meaningful difference of 2 in NRS between the arms. We decided to plan enrollment of 20 subjects per arm for potential loss during this randomized, double-blinded, single-center, sham block trial.
- Potential subjects undergoing arthroscopy will have their electronic medical record reviewed by the study team to look for exclusion criteria. If the subject is excluded, then they will be added to the Screening Log with date and reason for their exclusion. If all inclusion criteria are met, then the subject will be approached in the Regional Anesthesia area for their consent. A copy of the consent will be given to the study subject. The other informed consent document will be maintained by the study team in the research files.
- Patients will be asked to provide baseline pain scores both, at rest and with movement, on a scale of 0-10 (0 being no pain and 10 being the worst pain). Preoperative opioid use including drug(s), dosage and frequency will be recorded. Randomization of patients will then occur through the use of sequentially numbered envelopes with only those directly involved in the care of the patient during block placement being aware of which arm of the study the patient has been randomized. Those members of the study team who will be collecting post-operative data will be blinded to the randomization.
Standard American Society of Anesthesiology monitors and oxygen will be applied. Unless there is a contraindication, each patient will receive 650mg "milligrams" of oral acetaminophen. To standardize the effect on postoperative pain, ketamine will not be given as a preoperative sedation medication or intraoperative medication. No long acting opioids will be given in the operating room or post-anesthesia care unit. Intraoperative fentanyl will be limited to 5 micrograms per kg "kilogram". Intraoperative dexamethasone will not be given for post-operative nausea/vomiting prophylaxis.
Subjects will be sedated as per usual practice and will also be blinded to their randomization. All peripheral nerve blocks will be performed by a resident or fellow under supervision by an attending anesthesiologist. The attending anesthesiologist may perform the procedures alone. All volumes and concentrations of nerve block mixtures administered will be identical to assist in the blinding process.
All 40 subjects will receive an ultrasound guided interscalene nerve block using 20mL "milliliters" of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. The intervention arm, consisting of 20 patients, will additionally receive the following: 10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine at the PECS2 location as described by Blanco, et al.3,4 All procedures will be performed under a sterile technique including the use of chlorhexidine prep of the skin, sterile gloves, sterile ultrasound probe covers with sterile ultrasound gel, a cap and a mask. For the interscalene block, a 21 gauge 90mm "millimeter" stimulating block needle will be directed, under real-time ultrasound guidance, into the interscalene muscle space at the level of the 5th and 6th cervical nerve roots. Twenty mL of the above local anesthetic mixture will be dosed incrementally, aspirating every 5 mL, to surround the upper trunk of the brachial plexus. For the PECS 1 \& 2 block, a 21 gauge 90mm stimulating block needle will be placed under real-time ultrasound guidance at approximately the level of the 4th and 5th ribs near the mid-axillary line. The needle will be advanced into a tissue plane between the serratus anterior muscle and the pectoralis minor muscle. Twenty mL of the same local anesthetic mixture will be dosed incrementally, every 5 mL, to spread within this PEC2 space. The needle will be withdrawn, following the first injection, to a tissue plane between the pectoralis minor and pectoralis major muscles. Ten mL of the same local anesthetic mixture will be dosed incrementally, every 5 mL, to spread within this PEC1 space.
Fifteen and 30 minutes (if no change at 15min) following block placement, success will be assessed by absence/decrease of pin-prick sensation to a 25 gauge Whitacre needle in the following manner:
Cutaneous sensation will be tested over the deltoid region to assess for successful interscalene block.
Cutaneous sensation will be tested over the lateral aspect of the pectoralis muscles at the level of the nipple.
Scoring of sensation will be the following: 0= full sensation, 1= partial sensation, 2= no sensation (complete block) Following block placements, the subjects will be transported to the OR and general anesthesia will be induced. Following intubation, surgical procedure, emergence and extubation, the subject will be transported to the recovery room. In the recovery room or via phone post-discharge, at the 6 hour mark post-block placement, we will ask the subject if they are having any axillary pain. The severity of pain will be determined using the Numerical Rating Scale of 0-10. Zero is no pain and 10 is the most pain possible. Total opiate and benzodiazepine doses will be charted for the preoperative, intraoperative and PACU time frames.
- Conditions
- Biceps Tendonitis
- Being tested
- PECS "Pectoralis" 1 and 2 Blocks, Interscalene Block, Sham Block, Solution for Injection in Interscalene Block, Solution for Injection in Sham Block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PECS "Pectoralis" 1 and 2 BlocksProcedure or surgery
An interscalene and a PECS "Pectoralis" 1 and 2 block will be performed on the subjects.
Interscalene BlockProcedure or surgery
An interscalene block will be performed on the subjects.
Sham BlockProcedure or surgery
Solution for Injection in Interscalene BlockDrug
Also called bupivacaine, epinephrine, clonidine
20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine
Solution for Injection in Sham BlockDrug
Also called Lidocaine
Lidocaine 1%
Solution for Injection PECS BlocksDrug
Also called bupivacaine, epinephrine, clonidine
10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location
| Study group | Role | What they receive |
|---|---|---|
| Interscalene Block plus Sham Block | Sham comparator | Twenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS "Pectoralis" block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block. Receives: Procedure: Interscalene Block; Procedure: Sham Block; Drug: Solution for Injection in Interscalene Block; Drug: Solution for Injection in Sham Block |
| Interscalene plus PECS Blocks | Active comparator | Twenty patients will receive an ultrasound guided interscalene nerve block Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. For the Intervention, these subjects will also a PECS "Pectoralis" 1 and 2 Blocks using the Solution for Injection PECS Blocks, dosed at the PECS1 location and PECS2 location as described by Blanco, et al. Receives: Procedure: PECS "Pectoralis" 1 and 2 Blocks; Procedure: Interscalene Block; Drug: Solution for Injection in Interscalene Block; Drug: Solution for Injection PECS Blocks |
What is being measured
The primary outcome is the main question the study is designed to answer.
Post-operative Axillary Pain
Post-operative ambulatory surgery subjects will be asked 6 hours after block placement about the presence of axillary pain at rest. Numerical Rating Scale scores (0-10) will be recorded with 0= no pain, 10=most pain possible. Higher scores denotes worse outcome.
Measured: 6 hours post-block.
Secondary outcomes (4)
Numerical Rating Scale Pain Scores (0-10) at Rest
Subjects were asked about their overall shoulder pain during the followup phone call at 24hrs post-block. Numerical Rating Scale scores (0-10) will be recorded with 0= no pain, 10=most pain possible. Higher scores denotes worse outcome.
Measured: Assessed 24hrs post-block on a scale from 0-10.
Percentage of Participants With Episodes of Nausea or Vomiting
Any episodes during the first 24 hours will be recorded as a yes.
Measured: Assessed 24hrs post-block (yes/no)
Total Opioid Usage
Recorded in oxycodone equivalents in the first 24 hours post-discharge from the PACU.
Measured: Assessed 24hrs post-block in mg
Time From Block Placement to Onset of Axillary Pain
Time self-reported by patients in the Interscalene Plus PECS Blocks group during data collection phone call at 24 hours post-block.
Measured: Assessed 24hrs post-block in hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2016 (estimated)
- Study startApr 2016
- Primary completion29 Jun 2017
- Study completion29 Jun 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Biceps TendonitisStudies of the same condition, open and under way.
- More trials run by Wake Forest University Health SciencesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Wake Forest University Health Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- J.Wells Reynolds, MD, Principal investigator, Wake Forest Baptist Health Department of Anesthesiology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02741713
- Sponsor's protocol ID
- IRB00030173
- Status last verified
- Jul 2018
- First submitted
- 7 Apr 2016
- Last updated
- 27 Aug 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Reynolds JW, Henshaw DS, Jaffe JD, Dobson SW, Edwards CJ, Turner JD, Weller RS, Graves BR, Freehill MT. Analgesic Benefit of Pectoral Nerve Block II Blockade for Open Subpectoral Biceps Tenodesis: A Randomized, Prospective, Double-Blinded, Controlled Trial. Anesth Analg. 2019 Aug;129(2):536-542. doi: 10.1213/ANE.0000000000004233.
PubMed 31136331
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery
- ClinicalTrials.gov ID
- NCT02741713
- Acronym / sponsor ID
- IRB00030173
- Conditions
- Biceps Tendonitis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Wake Forest University Health SciencesUniversity, hospital or other
- Study start
- Apr 2016 (actual)
- Primary completion
- 29 Jun 2017 (actual)
- Study completion
- 29 Jun 2017 (actual)
- First posted
- 18 Apr 2016 (estimated)
- Results
- Posted 27 Aug 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The standard practice for arthroscopic shoulder surgery at our institution is a general anesthetic with a long-acting interscalene block for post-operative pain control, which can reduce the amount of opiates needed after surgery. The interscalene block is effective in providing analgesia to the majority of the shoulder joint and has been shown to reduce post-operative pain scores after arthroscopic shoulder surgeries. However, there is a subset of arthroscopic shoulder surgery patients who have pain in the axilla even in the setting of a functioning interscalene brachial plexus nerve block. One of our surgeons has reported a high incidence of axillary pain in patients who undergo a sub-pectoral biceps tenodesis as part of their arthroscopic procedure. A newly described nerve block approach to the nerves that supply sensation to the axillary region called the PECS "Pectoralis" 1 \& 2 block may provide additional analgesia to these patients.
The purpose of this prospective, randomized, observer and patient blinded, single-center, sham block trial is to determine if the addition of PECS blocks to an interscalene block will reduce the severity of axillary pain following arthroscopic shoulder surgery that involves a sub-pectoral biceps tenodesis. Secondarily, the study will assess the duration of PECS 1 \& 2 and whether the block reduces post-operative opioid usage. We hypothesize that the addition of the PECS 1 \& 2 block will reduce the severity of axillary pain at 6hrs and reduce postoperative narcotic usage for the first 24 hours.
Detailed description
Subjects that meet the inclusion criteria will be assigned a group by using a random numbers generator. All subjects will receive the standard practice at our institution of an interscalene brachial plexus block along with a general anesthetic. The intervention arm will get an additional local anesthetic block targeting nerves that we presume cover the axillary region (PECS "Pectoralis" 1 \& 2). These nerves in the upper chest are the lateral branches of the 2nd to 5th intercostal nerves, which includes the intercostobrachial nerve. The anesthesiologist placing the nerve blocks will be un-blinded to perform the procedures. Both the surgeon and the Acute Pain Service anesthesiologist will be blinded as to whether or not the intervention was provided to any given subject. The Acute Pain Service team will remain blinded and collect the data outcomes.
Initially, pilot data was collected in a total of ten patients with five patients randomized to each arm. Primary endpoint was NRS "Numerical Rating Scale" of 0-10 at 6hrs after block placement. Our pilot data indicate that the mean NRS is about 5 for the control group, with a standard deviation of 1.4. Using a two-sided two-sample t test (an alpha of 0.05 and power of 0.95), we conservatively estimate that 14 subjects per arm will be needed to detect a clinically meaningful difference of 2 in NRS between the arms. We decided to plan enrollment of 20 subjects per arm for potential loss during this randomized, double-blinded, single-center, sham block trial.
- Potential subjects undergoing arthroscopy will have their electronic medical record reviewed by the study team to look for exclusion criteria. If the subject is excluded, then they will be added to the Screening Log with date and reason for their exclusion. If all inclusion criteria are met, then the subject will be approached in the Regional Anesthesia area for their consent. A copy of the consent will be given to the study subject. The other informed consent document will be maintained by the study team in the research files.
- Patients will be asked to provide baseline pain scores both, at rest and with movement, on a scale of 0-10 (0 being no pain and 10 being the worst pain). Preoperative opioid use including drug(s), dosage and frequency will be recorded. Randomization of patients will then occur through the use of sequentially numbered envelopes with only those directly involved in the care of the patient during block placement being aware of which arm of the study the patient has been randomized. Those members of the study team who will be collecting post-operative data will be blinded to the randomization.
Standard American Society of Anesthesiology monitors and oxygen will be applied. Unless there is a contraindication, each patient will receive 650mg "milligrams" of oral acetaminophen. To standardize the effect on postoperative pain, ketamine will not be given as a preoperative sedation medication or intraoperative medication. No long acting opioids will be given in the operating room or post-anesthesia care unit. Intraoperative fentanyl will be limited to 5 micrograms per kg "kilogram". Intraoperative dexamethasone will not be given for post-operative nausea/vomiting prophylaxis.
Subjects will be sedated as per usual practice and will also be blinded to their randomization. All peripheral nerve blocks will be performed by a resident or fellow under supervision by an attending anesthesiologist. The attending anesthesiologist may perform the procedures alone. All volumes and concentrations of nerve block mixtures administered will be identical to assist in the blinding process.
All 40 subjects will receive an ultrasound guided interscalene nerve block using 20mL "milliliters" of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. The intervention arm, consisting of 20 patients, will additionally receive the following: 10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine at the PECS2 location as described by Blanco, et al.3,4 All procedures will be performed under a sterile technique including the use of chlorhexidine prep of the skin, sterile gloves, sterile ultrasound probe covers with sterile ultrasound gel, a cap and a mask. For the interscalene block, a 21 gauge 90mm "millimeter" stimulating block needle will be directed, under real-time ultrasound guidance, into the interscalene muscle space at the level of the 5th and 6th cervical nerve roots. Twenty mL of the above local anesthetic mixture will be dosed incrementally, aspirating every 5 mL, to surround the upper trunk of the brachial plexus. For the PECS 1 \& 2 block, a 21 gauge 90mm stimulating block needle will be placed under real-time ultrasound guidance at approximately the level of the 4th and 5th ribs near the mid-axillary line. The needle will be advanced into a tissue plane between the serratus anterior muscle and the pectoralis minor muscle. Twenty mL of the same local anesthetic mixture will be dosed incrementally, every 5 mL, to spread within this PEC2 space. The needle will be withdrawn, following the first injection, to a tissue plane between the pectoralis minor and pectoralis major muscles. Ten mL of the same local anesthetic mixture will be dosed incrementally, every 5 mL, to spread within this PEC1 space.
Fifteen and 30 minutes (if no change at 15min) following block placement, success will be assessed by absence/decrease of pin-prick sensation to a 25 gauge Whitacre needle in the following manner:
Cutaneous sensation will be tested over the deltoid region to assess for successful interscalene block.
Cutaneous sensation will be tested over the lateral aspect of the pectoralis muscles at the level of the nipple.
Scoring of sensation will be the following: 0= full sensation, 1= partial sensation, 2= no sensation (complete block) Following block placements, the subjects will be transported to the OR and general anesthesia will be induced. Following intubation, surgical procedure, emergence and extubation, the subject will be transported to the recovery room. In the recovery room or via phone post-discharge, at the 6 hour mark post-block placement, we will ask the subject if they are having any axillary pain. The severity of pain will be determined using the Numerical Rating Scale of 0-10. Zero is no pain and 10 is the most pain possible. Total opiate and benzodiazepine doses will be charted for the preoperative, intraoperative and PACU time frames.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Interscalene Block plus Sham Block | Sham comparator | Procedure: Interscalene Block, Procedure: Sham Block, Drug: Solution for Injection in Interscalene Block, Drug: Solution for Injection in Sham BlockTwenty subjects will receive an ultrasound guided interscalene nerve block using the Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. A Sham Block of in area of PECS "Pectoralis" block will be done to allow for assessment of the intervention. Using the Solution for Injection in Sham Block. |
| Interscalene plus PECS Blocks | Active comparator | Procedure: PECS "Pectoralis" 1 and 2 Blocks, Procedure: Interscalene Block, Drug: Solution for Injection in Interscalene Block, Drug: Solution for Injection PECS BlocksTwenty patients will receive an ultrasound guided interscalene nerve block Solution for Injection in Interscalene Block dosed at the upper trunk location near the 6th cervical vertebral level, per standard clinical practice. For the Intervention, these subjects will also a PECS "Pectoralis" 1 and 2 Blocks using the Solution for Injection PECS Blocks, dosed at the PECS1 location and PECS2 location as described by Blanco, et al. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adults, between 18 and 80 years of age
- Ability to take pills
- Agreement to a regional with general anesthesia technique
Key exclusion criteria (8 listed)
- Allergy to amide local anesthetics
- Presence of a progressive neurological deficit
- pre-existing coagulopathy
- Current infection
- Significant pulmonary disease contraindicating phrenic nerve blockade
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PECS "Pectoralis" 1 and 2 BlocksAn interscalene and a PECS "Pectoralis" 1 and 2 block will be performed on the subjects. | Procedure or surgery | Interscalene plus PECS Blocks |
| Interscalene BlockAn interscalene block will be performed on the subjects. | Procedure or surgery | Interscalene Block plus Sham Block, Interscalene plus PECS Blocks |
| Sham Block | Procedure or surgery | Interscalene Block plus Sham Block |
| Solution for Injection in Interscalene BlockAlso: bupivacaine, epinephrine, clonidine20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine | Drug | Interscalene Block plus Sham Block, Interscalene plus PECS Blocks |
| Solution for Injection in Sham BlockAlso: LidocaineLidocaine 1% | Drug | Interscalene Block plus Sham Block |
| Solution for Injection PECS BlocksAlso: bupivacaine, epinephrine, clonidine10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location | Drug | Interscalene plus PECS Blocks |
Primary outcome
Post-operative Axillary Pain
Time frame: 6 hours post-block.
Post-operative ambulatory surgery subjects will be asked 6 hours after block placement about the presence of axillary pain at rest. Numerical Rating Scale scores (0-10) will be recorded with 0= no pain, 10=most pain possible. Higher scores denotes worse outcome.
4 secondary outcomes
Numerical Rating Scale Pain Scores (0-10) at Rest
Time frame: Assessed 24hrs post-block on a scale from 0-10.
Percentage of Participants With Episodes of Nausea or Vomiting
Time frame: Assessed 24hrs post-block (yes/no)
Total Opioid Usage
Time frame: Assessed 24hrs post-block in mg
Time From Block Placement to Onset of Axillary Pain
Time frame: Assessed 24hrs post-block in hours
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 31136331Reynolds JW, Henshaw DS, Jaffe JD, Dobson SW, Edwards CJ, Turner JD, Weller RS, Graves BR, Freehill MT. Analgesic Benefit of Pectoral Nerve Block II Blockade for Open Subpectoral Biceps Tenodesis: A Randomized, Prospective, Double-Blinded, Controlled Trial. Anesth Analg. 2019 Aug;129(2):536-542. doi: 10.1213/ANE.0000000000004233.
- Individual participant dataSharing planned: No
Related trials for Biceps Tendonitis
Recruiting
Electroacupuncture and Cupping for Shoulder Tendinitis
Shoulder Tendinopathy, Shoulder Tendinitis
Recruiting
Functional Results of Infiltration for Biceps Tendonitis Guided by Ultrasound vs Anatomical Repairs: Variation in Technique
Bíceps Tendinitis
Not yet recruiting
Comparison of the Effectiveness Heavy Slow Resistance and Eccentric Training in Rotator Cuff Tendinopathy
Rotator Cuff Tendinopathy, Subacromial Impingement Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
J.Wells Reynolds, MD principal investigator
Wake Forest Baptist Health Department of Anesthesiology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing PECS "Pectoralis" 1 and 2 Blocks, Interscalene Block and Solution for Injection in Interscalene Block in people with Biceps Tendonitis, run by Wake Forest University Health Sciences at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 27 Aug 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Post-operative Axillary Pain (time frame: 6 hours post-block.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02741713, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2018.